 | Up a level |
Tettero, Jesse M; Buisman, Yara; Ngai, Lok Lam; Bachas, Costa; Gjertsen, Bjorn T; Kelder, Angèle; van de Loosdrecht, Arjan A; Manz, Markus G; Pabst, Thomas; Scholten, Willemijn; Ossenkoppele, Gert J; Cloos, Jacqueline; de Leeuw, David C (2023). Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML. HemaSphere, 7(12), e981. Wolters Kluwer Health 10.1097/HS9.0000000000000981
Ngai, Lok Lam; Hanekamp, Diana; Janssen, Fleur; Carbaat-Ham, Jannemieke; Hofland, Maaike A M; Fayed, Mona M H E; Kelder, Angèle; Oudshoorn-van Marsbergen, Laura; Scholten, Willemijn J; Snel, Alexander N; Bachas, Costa; Tettero, Jesse M; Breems, Dimitri A; Fischer, Thomas; Gjertsen, Bjorn T; Griskevicius, Laimonas; Juliusson, Gunnar; van de Loosdrecht, Arjan A; Maertens, Johan A; Manz, Markus G; ... (2023). Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial. Blood, 141(21), pp. 2657-2661. American Society of Hematology 10.1182/blood.2022019160
Janssen, Jeroen; Löwenberg, Bob; Manz, Markus; Bargetzi, Mario; Biemond, Bart; Borne, Peter von dem; Breems, Dimitri; Brouwer, Rolf; Chalandon, Yves; Deeren, Dries; Efthymiou, Anna; Gjertsen, Bjørn-Tore; Graux, Carlos; Gregor, Michael; Heim, Dominik; Hess, Urs; Hoogendoorn, Mels; Jaspers, Aurelie; Jie, Asiong; Jongen-Lavrencic, Mojca; ... (2021). Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers, 13(4) MDPI AG 10.3390/cancers13040672
